The number of people living with Huntington disease is expected to continue increasing. By 2030, half what was happening in 2012 in the U.S. will occur, potentially. In the future, it's going to be important to be able to find a way to cure this disease.
Huntingtons disease is a progressive neurodegeneration. A clinical examination may reveal signs of Huntington's disease, including slow and weak gait; enlarged eyes; dyspnea; tremor; and spasticity. Psychiatric features may be present, including mood alterations with irritability, paranoia, and cognitive impairment. Psychiatric evaluation and screening are recommended for every patient receiving a Huntington's disease diagnosis.
We found that the average age of onset for people with Huntington disease was approximately 27 years. The prevalence of Huntington disease in the general population in the United States is unknown and it is likely that the true number of cases is higher than currently reported.
No cure for HD exists. The disease is mainly managed through management of symptoms and support for patients and families. There is an emphasis on early diagnosis, with an eye toward treatments that have the potential to delay or limit symptom development and minimize the rate of cognitive decline.
Huntington disease can be effectively and successfully cured, even if the patient is still alive when the procedure is undertaken. In view of these successes, a similar strategy should be considered for the treatment of other neurodegenerative disorders affecting more than one hundred families worldwide, although it will likely be impractical in many cases.
HD is an inherited, neurodegenerative disease that causes cognitive, behavioural, and neuropsychological problems. Most cases are not diagnosed before the age of 40, with a mean onset of diagnosis for affected individuals at age 29. The condition is characterized by the presence of abnormal (fibrillar) protein deposits in the nucleus precerebellar region. Current research focuses on the function of these abnormal protein deposits and on whether and how this contributes to HD pathogenesis.\n
A significant number of patients with HD may have a normal neuroimaging study or neuropsychological profile. This may suggest that neurodegeneration is caused by environmental stresses, other disease processes, or an underlying genetic problem in some way. It may also suggest heterogeneity in the disease because of factors other than an underlying neurological disease process. Future research will likely incorporate a broad-based approach to investigate the potential contribution of environmental and hereditary factors in order to better determine the nature and course of HD and to search for treatments and strategies for its prevention.
It must be noted that, in the present study, only one of the two trials discussed indicated that a branapram + tranzodone (HTT-8) combination showed promise. The authors suggest the use of branapram in combination with medications which have an effect on cholinergic tone such as, tramadol, atropine sulfate, acetylcholinesterase inhibitors such as rasagiline or cholinesterase inhibitors such as rivastigmine in patients with moderate-to-severe HD with a motor-based dyskinesia symptom scale score greater than or equal to 2 or a score for overall QADL equal to 35.
In a recent study, findings and conclusions of the studies have been reviewed to date. The authors also highlight promising results from ongoing ongoing studies, that may yield more significant conclusions on the benefits of branaplam therapy for the treatment of patients with Huntington's disease. Additional randomized controlled trials are required to confirm the efficacy of branaplam and to exclude the possibility of branaplam causing harm.
Branaplam has significant and significant efficacy in decreasing motor and cognitive symptoms of dementia. Further studies should be performed to verify if these effects are maintained for a longer period of time as well as to find out whether the beneficial effects are comparable to other antidiemental drugs like donepezil.
Almost all the patients developed adverse drug reactions at the doses of branaplam prescribed, including nausea, vomiting, dizziness, headache, and other hypersensitivity reactions, most of which were mild or moderate. Patients may experience insomnia after taking branaplam. Further evaluation is required regarding the role of plasma concentrations in adverse reactions, but no reliable data is available about branaplam and drug interactions, so clinicians should continue to prescribe branaplam as a first-line therapy according to the recommended use of branaplam and carefully monitor patients’ symptoms, plasma concentrations, and renal functions.